NCT01026376: An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) |
|
|
| No Longer Available | N/A | | RoW | decitabine | Janssen-Cilag Farmaceutica Ltda., Janssen Korea, Ltd., Korea | Myelodysplastic Syndromes | 11/11 | 11/11 | | |
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |
HEMATO-BIO, NCT02320656: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders--IPC-2013-015 |
|
|
| Recruiting | N/A | 650 | Europe | Blood sampling, Bone marrow aspirate, Skin biopsy, Buccal swab | Institut Paoli-Calmettes | Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders | 05/19 | 05/24 | | |
